• Co-Founder Dr. Henk-Jan Boele appointed as Managing Director
• Appointment aligns with progress of pivotal FDA 510(k) trial and early commercialization
• Non-Executive Director Ms. Jane Morgan resigns to focus on other commitments

Blinklab Ltd, an Australian digital health innovator focused on developing objective diagnostic technologies for neurodevelopmental conditions, has announced changes to its Board of Directors. The company has appointed Co-Founder and CEO, Dr. Henk-Jan Boele, as the new Managing Director. This appointment is intended to ensure clear leadership and strategic alignment as Blinklab completes its pivotal FDA study and progresses towards early commercialization. Dr. Boele, a Medical Doctor and PhD in neuroscience, has led the company since its inception in 2021, guiding it through its ASX listing. Under his leadership, Blinklab has achieved several critical milestones, including de-risking the regulatory pathway for its BlinkLab Dx 1 technology, establishing a network of U.S. clinical sites for its upcoming FDA 510(k) trial, and engaging with capital markets and the investment community. The company also announces the resignation of Non-Executive Director Ms. Jane Morgan, who will be focusing on other professional commitments in 2026. Ms. Morgan has played an important role in establishing Blinklab's profile and credibility within the Australian capital markets during its first 20 months as an ASX-listed company.

The company is advancing toward its most significant milestone, the imminent start of the pivotal FDA 510(k) regulatory trial for its BlinkLab Dx 1 technology, which is aimed at diagnosing autism in children.